News

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic

The biotech company reported record second-quarter revenue fueled by strong sales of its cancer therapy Amtagvi.

Record quarterly revenue, improving margins and continued commercial momentum are prompting Iovance to reassess its full-year guidance while advancing multiple late-stage clinical programmes. Key Investor TakeawaysIovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue of approximately $99.

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arvinas (ARVN) delivered earnings and revenue surprises of +1,175.00% and +562.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics stock has rebounded strongly in the short term, yet its longer track record and current valuation checks paint a more mixed picture that investors need to weigh carefully. After a steep multi year share price decline, the broader valuation framework now points to Iovance as screening cheap on several measures. Iovance Biotherapeutics shares have declined 82.7% over the past 5 years, which highlights how much long term holders have been hurt and why any apparent value...

Iovance Biotherapeutics recently announced it will report its second quarter 2026 results and corporate updates on August 6, 2026, drawing attention as Wall Street anticipates a quarterly loss alongside higher year-over-year revenue. Analysts’ earnings revisions and a negative Earnings ESP highlight uncertainty around the upcoming report, even as interest in Iovance’s TIL-based Amtagvi® therapy and broader pipeline remains elevated. Next, we’ll examine how this upcoming earnings release and...

Iovance Biotherapeutics (IOVA) is drawing attention ahead of its second quarter 2026 earnings report and corporate update scheduled for August 6, 2026, which will be presented alongside its first FDA-approved T cell therapy for solid tumors. See our latest analysis for Iovance Biotherapeutics. The latest pullback in Iovance Biotherapeutics, with a 1-day share price return down 13.22% and 7-day share price return down 18.44% to US$4.07, sits against a stronger backdrop that includes a 30-day...

Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Apogee Therapeutics Inc. (APGE) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Best Penny Stocks to Invest In According to Billionaires. Recently, on June 30, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) updated its corporate presentation, highlighting its position as a global leader in tumor-infiltrating lymphocyte cell therapy. ​The update noted that the company has now treated more than 1,500 patients through […]

The biotech is clearly innovative, but sometimes that's not enough.

Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 10 Resilient Stocks Beating Market Slump. Iovance Biotherapeutics saw its share prices increase by 9.36 percent to close at $4.44 apiece, as investors positioned portfolios ahead of the end of the second quarter, supported by a recent regulatory approval that opened the door for its expansion into […]

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Best Penny Stocks That Could Skyrocket in 2026. On June 4, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) with a price target of $9. The analyst noted two key positive developments for AMTAGVI, which is Iovance’s lead therapy. ​Firstly, AMTAGVI […]

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is among the hidden penny stocks to invest in. As of June 10, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was trading near the low levels reported on June 3, before the stock appreciated following the Australian approval of Amtagvi. The stock has returned to its pre-approval levels. On June 4, TheFly reported that Iovance […]

While Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has gained 54.95% year-to-date, analysts continue to see 112.80% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. Two meaningful pipeline and regulatory developments arrived within days of each other, adding fresh momentum to Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s expanding TIL therapy platform. […]

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the top penny stocks to buy in investors’ stock portfolio. On June 1, research firm Citizens reiterated a Market Outperform rating on Iovanace Biotherapeutics (NASDAQ:IOVA) with a $5 price target. The research firm remains confident about the company’s outlook, impressed by the real-world presentation at ASCO that broadened […]

Iovance Biotherapeutics (IOVA) is back in focus after Australia’s Therapeutic Goods Administration granted conditional approval for Amtagvi, a tumor infiltrating lymphocyte therapy for previously treated unresectable or metastatic melanoma in a high incidence market. See our latest analysis for Iovance Biotherapeutics. The TGA decision comes after a volatile period, with the stock delivering a 67.86% year to date share price return and a 106.34% total shareholder return over one year...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 8, Chardan reiterated Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) as a Buy but lowered its price target of the stock to $14 from $16. The price target cut is in response to Amtagvi’s launch guidance. The company delivered […]

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 9 Stocks Crushing the Market With Surging Returns. Iovance Biotherapeutics climbed by 15.57 percent on Thursday to end at $4.38 apiece after securing the conditional approval of Australia’s Therapeutic Goods Administration (TGA) for the treatment of melanoma through its therapy, Amtagvi. The approval marked Iovance Biotherapeutics Inc.’s (NASDAQ:IOVA) […]

Tread carefully, but certain factors make this speculative biotech play stand out.

Iovance Biotherapeutics recently received FDA clearance to proceed with an investigational new drug application for IOV-5001, a next-generation IL-12 tethered tumor infiltrating lymphocyte therapy, enabling a Phase 1/2 trial in advanced colorectal, triple-negative, estrogen receptor-low breast cancers and other solid tumors. The therapy’s design to localize IL-12 expression within tumors, by tethering it to TIL cell surfaces, highlights Iovance’s push to refine efficacy while aiming to limit...

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

Stock move puts Iovance Biotherapeutics (IOVA) back in focus Iovance Biotherapeutics (IOVA) has drawn attention after recent trading, with the stock closing at $4.11 and posting double-digit total returns over the past month and the past three months. See our latest analysis for Iovance Biotherapeutics. The recent 1-day share price return of 11.08% and 7-day share price return of 19.13%, on top of a 63.10% year to date share price return, point to building momentum, although the 3-year total...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 7, 2026, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported Q1 EPS of (19c), versus the consensus estimate of (15c). Revenue totaled $71.43M, versus the consensus estimate of $75.66M. Interim President and Chief Executive Officer Frederick Vogt said the […]